Start-up: This German start-up wants to become the next mRNA pioneer
In one of the largest European biotech seed rounds, SRTD raises €31.5 million. The lead investor sees synergies with Biontech. This is not only medically significant.
SRTD, a biotech company based in Jülich near Aachen, has secured €31.5 million in seed funding to develop medications using a new generation of mRNA technology. The funding round was led by French investment company Mérieux Equity Partners, with participation from Boehringer Ingelheim Venture Fund, Lilly Ventures, High-Tech Gründerfonds, and NRW Bank.
SRTD's technology aims to target and kill or reprogram diseased cells while sparing healthy tissue, making treatments safer and more targeted, particularly for aggressive tumors. The company plans to use the funding to advance the development of therapeutics for oncology, autoimmune, and fibrosis diseases, with the first clinical trial expected to start in 2029.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
